Journal
EUROPEAN NEUROPSYCHOPHARMACOLOGY
Volume 12, Issue 6, Pages 581-586Publisher
ELSEVIER
DOI: 10.1016/S0924-977X(02)00107-4
Keywords
neuroinflammation; positron emission tomography; [C-11](R)-PK11195
Ask authors/readers for more resources
We briefly outline the rationale for employing positron emission tomography (PET), using the ligand [C-11](R)-PK11195, the binding site for which is highly expressed by activated microglia, in order (a) to detect in vivo neuroinflammatory changes occurring in a variety of brain diseases and at different disease stages and (b) to monitor the progression of neuroinflammation as a generic in vivo marker of 'disease activity'. The use of [C-11](R)-PK11195 PET is described as a systematic attempt at measuring the emerging phenomenology of tissue pathology itself-as opposed to measuring, for example, the loss of neuronal function or structure-and as a proof of principle for the clinical utility of imaging glial cells in vivo. (C) 2002 Elsevier Science B.V./ECNP All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available